Phase I Study of Precision CRT for Liver-Dominant Metastatic Pancreatic Cancer With Homologous Recombination Deficiency (PreCISeRT)
The purpose of this phase I trial is to evaluate the safety and efficacy of the combination of conformal radiation therapy (RT) and Gemcitabine and Cisplatin in patients with metastatic pancreatic cancer that has spread to the liver.
Study ID: 21-443
Trial Phase: Phase I
Trial Sponsor: Memorial Sloan Kettering
Therapies Used in This Trial: Gemcitabine, Cisplatin